Risk factor
Limited trading liquidity
Profitability factor
Greatly undervalued vs peers
About
Based in Seoul, South Korea, Boryung Corporation is a pharmaceutical company dedicated to the creation, manufacturing, and distribution of a diverse range of medical products. Their comprehensive offerings include treatments for cardiovascular ailments, oncology drugs, gastrointestinal therapies, and crucial active pharmaceutical ingredients (APIs). Established in 1957, the firm boasts a considerable global footprint, exporting its pharmaceuticals to approximately 50 countries across six continents. Notable international markets include Japan, China, the vast regions of Southeast Asia and the Middle East, in addition to Europe, South America, and Africa. The company officially transitioned its name from Boryung Pharmaceutical Co., Ltd. to its current designation, Boryung Corporation, in March 2022.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD
Target Price
The average target price of 003850.KS is 14000 and suggests 58.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation t